# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 4069
- Completion tokens: 27040
- Reasoning tokens: 
- Total tokens: 31109
- API requests reported: 
- Elapsed seconds: 249.391
- Final benchmark system: raw; file rank 3/5; original repeat 5; model vendor: DeepSeek

---
All statistical statements below refer to the supplied disease-state table: ulcerative colitis (UC) versus healthy control colonic mucosal tissue. Positive log2FC means higher expression in UC; negative log2FC means lower expression in UC. No prognostic hazard-ratio data were provided, so no prognostic conclusions are made.

## 1. Overall biological interpretation

The UC mucosal transcriptome is dominated by two opposing, coordinated shifts:

- **Upregulation of innate inflammatory, antimicrobial-alarmin, chemokine, and tissue-remodeling programs.** The strongest signals include S100A8, LCN2, CHI3L1, CXCL1/2/3, DUOX2/DUOXA2, PLA2G2A, MMP3, TIMP1, TNC, PDPN, PRRX1, and SERPINB5. This is consistent with active neutrophilic inflammation, epithelial stress, antimicrobial host defense, and mucosal matrix remodeling.
- **Broad downregulation of a mature colonocyte differentiation program.** The strongest downregulated genes include AQP8, SLC51A, SLC16A1, SLC38A4, SLC23A1/3, ABCG2, CYP2B6, UGT2A3, HMGCS2, G6PC, TAT, and MEP1B. This suggests loss of differentiated absorptive, metabolic, detoxifying, and barrier functions in the colonic epithelium.

A third, less dominant but reproducible signal is **adaptive immune activation**, including immunoglobulin expression, DAPP1, and CTLA4. This fits with the known B-cell/plasma-cell and regulatory T-cell components of UC.

Overall, the transcriptomic picture is not a single “inflammatory” response but a mucosal injury phenotype: innate/adaptive immune activation plus epithelial dedifferentiation and metabolic suppression.

---

## 2. Core biological programs

### Program 1: Innate inflammatory, alarmin, and antimicrobial-neutrophil response
- **Direction:** Upregulated in UC  
- **Major supporting genes:** S100A8, S100P, LCN2, CHI3L1, PI3, PLA2G2A, VNN1, DUOX2, DUOXA2, CXCL1, CXCL2, CXCL3, plus negative regulators IL1RN, SOCS3, IRAK3  
- **Most appropriate pathway:** Hallmark “Inflammatory Response”; KEGG “IL-17 signaling pathway”; GO “neutrophil chemotaxis”  
- **Explanation:** S100A8, LCN2, and CHI3L1 are alarmins/antimicrobial proteins strongly associated with intestinal inflammation. CXCL1/2/3 are ELR+ chemokines that recruit neutrophils via CXCR2. DUOX2/DUOXA2 generate antimicrobial reactive oxygen species. PLA2G2A and VNN1 support lipid-derived inflammatory/defense signaling. IL1RN, SOCS3, and IRAK3 are endogenous feedback inhibitors of the same inflammatory axes. Together, these genes indicate a coordinated innate defense/neutrophilic inflammatory loop, not merely isolated gene changes.
- **Strength and limitations:** Very strong statistical support from many independent genes. The main limitation is that bulk mucosal tissue cannot distinguish whether these signals come from epithelium, neutrophils, macrophages, or other immune cells; some effect may reflect immune-cell infiltration rather than cell-intrinsic upregulation.

### Program 2: ECM remodeling, epithelial-mesenchymal plasticity, and fibrogenic response
- **Direction:** Upregulated in UC  
- **Major supporting genes:** MMP3, TIMP1, TNC, PDPN, PRRX1, CDH3, SERPINB5, TGM2, FILIP1L, IGDCC4  
- **Most appropriate pathway:** Hallmark “Epithelial–Mesenchymal Transition”; KEGG “ECM-receptor interaction”; Reactome “Degradation of the extracellular matrix”  
- **Explanation:** MMP3 degrades extracellular matrix and activates other proteases; TIMP1 is its endogenous inhibitor and is also profibrotic. TNC is a matricellular protein induced in wound healing and inflammation. PDPN, PRRX1, and SERPINB5 are linked to mesenchymal/EMT-like states, while CDH3 and TGM2 contribute to epithelial adhesion and matrix crosslinking. These genes collectively point to active mucosal remodeling, ulcer healing, and potentially fibrosis.
- **Strength and limitations:** Supported by multiple independent genes and coherent pathway annotations. The limitation is that MMP3, TNC, and PDPN can be expressed by immune, stromal, lymphatic, or myofibroblast cells; the precise cellular source and net proteolytic balance cannot be determined from this table.

### Program 3: Loss of mature colonocyte metabolic, transport, and detoxification identity
- **Direction:** Downregulated in UC  
- **Major supporting genes:** AQP8, SLC51A, SLC16A1, SLC38A4, SLC23A1, SLC23A3, SLC19A3, ABCG2, CYP2B6, UGT2A3, HMGCS2, G6PC, TAT, ACSF2, GBA3, TINCR  
- **Most appropriate pathway:** KEGG “Metabolic pathways”; KEGG “ABC transporters”; Reactome “Bile acid and bile salt metabolism”; GO “small molecule metabolic process”  
- **Explanation:** Healthy colonocytes express transporters and enzymes needed for water transport (AQP8), butyrate uptake (SLC16A1), bile-acid transport (SLC51A), vitamin transport (SLC23A1/3, SLC19A3), xenobiotic detoxification (CYP2B6, UGT2A3, ABCG2), ketogenesis (HMGCS2), and core metabolism (G6PC, TAT, ACSF2). Their simultaneous downregulation suggests a coordinated loss of differentiated absorptive/secretory function and a metabolic shift away from normal colonocyte energy metabolism.
- **Strength and limitations:** Strong statistical support and a broad, coherent set of genes. The main limitation is that this pattern may partly reflect epithelial damage/cell loss rather than a cell-autonomous transcriptional switch; single-cell or sorted-epithelial validation is needed.

### Program 4: Suppression of constitutive mucosal barrier and glycosylation-associated antimicrobial defense
- **Direction:** Downregulated in UC  
- **Major supporting genes:** DEFB1, B4GALNT2, GCNT2, MEP1B  
- **Most appropriate pathway:** KEGG “Mucin-type O-glycan biosynthesis”; GO “antimicrobial humoral response”; GO “O-glycan processing”  
- **Explanation:** DEFB1 encodes a constitutively expressed beta-defensin; B4GALNT2 and GCNT2 are glycosyltransferases involved in O-glycan modification that influence mucus barrier and microbe–host interactions; MEP1B is a brush-border metalloprotease. Downregulation of these genes suggests that the constitutive chemical/microbial barrier is suppressed, even while inducible antimicrobial/alarmin responses are increased.
- **Strength and limitations:** The gene set is smaller than in the other programs, but the direction is coherent and biologically relevant. The limitation is that this could largely reflect loss of mature surface epithelium in inflamed UC.

### Program 5: Adaptive immune activation with B-cell/plasma-cell and T-cell checkpoint signals
- **Direction:** Upregulated in UC  
- **Major supporting genes:** CTLA4, DAPP1, immunoglobulin heavy-chain probe (IGHV4-31|IGHM|IGHG1|IGH)  
- **Most appropriate pathway:** KEGG “B cell receptor signaling pathway”; KEGG “T cell receptor signaling pathway”; Reactome “Adaptive Immune System”  
- **Explanation:** The immunoglobulin probe and DAPP1, a B-cell receptor adaptor, point to B-cell/plasma-cell activation. CTLA4 is an inhibitory checkpoint receptor on regulatory/activated T cells. Together they indicate an adaptive immune component with a simultaneous regulatory/checkpoint brake. This fits the known UC phenotype of mucosal antibody production and regulatory T-cell involvement.
- **Strength and limitations:** Moderate gene support, but statistically strong. Important limitation: the immunoglobulin probe is ambiguous and may reflect plasma-cell infiltration; CTLA4 could be protective/regulatory rather than pathogenic.

---

## 3. Key genes and interaction modules

### 1. SLC6A14
- **Direction:** Strongly upregulated in UC (+4.85 log2FC)
- **Role:** Amino acid transporter induced by inflammatory cytokines; may support epithelial stress responses, proliferation, or amino-acid uptake during inflammation.
- **Gene-gene relationship:** No direct interaction can be inferred from this dataset. It is a pathway co-member with SLC38A4 (another amino acid transporter) but is directionally opposite, suggesting transporter reprogramming rather than a uniformly activated amino-acid transport program.

### 2. DUOX2 / DUOXA2
- **Direction:** Both upregulated in UC (DUOX2 +4.67; DUOXA2 +2.89)
- **Role:** DUOX2 is a dual oxidase generating hydrogen peroxide for antimicrobial defense; DUOXA2 is its maturation/ER factor. This module is central to epithelial ROS production and host defense.
- **Gene-gene relationship:** DUOXA2 is a known functional/regulatory partner required for DUOX2 maturation; direct physical interaction has been described in heterologous systems. The current dataset provides only co-expression, not direct interaction evidence.
- **Important caveat:** Loss-of-function DUOX2 mutations are associated with IBD-like disease, yet DUOX2 is upregulated in this active UC dataset. This may reflect compensatory induction or a shift from protective to excessive ROS production; directionality cannot be resolved from expression data alone.

### 3. S100A8 / LCN2 / CHI3L1 / S100P
- **Direction:** All upregulated in UC
- **Role:** Alarmins and antimicrobial/defense proteins. S100A8 is part of calprotectin; LCN2 is NGAL; CHI3L1 is YKL-40. They are associated with neutrophil infiltration, mucosal inflammation, and barrier defense.
- **Gene-gene relationship:** S100A8 physically heterodimerizes with S100A9 (not significant in this dataset); that direct interaction is known from protein literature. LCN2, CHI3L1, and S100P are co-expressed alarmin/defense molecules but no direct physical interaction is established here.

### 4. CXCL1 / CXCL2 / CXCL3 + IL1RN / SOCS3 / IRAK3
- **Direction:** Upregulated in UC
- **Role:** CXCL1/2/3 recruit neutrophils via CXCR2; IL1RN encodes IL-1 receptor antagonist; SOCS3 and IRAK3 are intracellular negative regulators of cytokine/TLR signaling. This module captures both pro-inflammatory chemokine signaling and its endogenous feedback control.
- **Gene-gene relationship:** CXCL1/2/3 are direct ligands for CXCR2 (ligand–receptor interaction). IL1RN directly antagonizes IL-1 receptor binding. SOCS3 and IRAK3 are intracellular regulators and are not physically linked to the chemokines; their co-expression represents pathway co-membership in inflammatory signaling.

### 5. MMP3 / TIMP1 / TNC / PDPN / PRRX1
- **Direction:** Upregulated in UC
- **Role:** Matrix remodeling, wound healing, EMT/fibrogenic response.
- **Gene-gene relationship:** MMP3 and TIMP1 have a known direct protease–inhibitor interaction. TNC can bind integrins and matrix proteins. PRRX1 is a transcription factor, not a direct binding partner of the matrix proteins. In this dataset, these genes are co-expressed and pathway co-members in ECM remodeling; direct physical interactions cannot be inferred from expression data alone.

### 6. Downregulated colonocyte transport/metabolism module
- **Direction:** Downregulated in UC
- **Genes:** AQP8, SLC51A, SLC16A1, HMGCS2, ABCG2, CYP2B6, UGT2A3, G6PC, TAT, ACSF2, SLC23A1, SLC38A4, SLC19A3
- **Role:** Loss of mature colonocyte metabolic, transport, and detoxification functions. Particularly notable are AQP8 (water transport), SLC16A1/MCT1 (butyrate uptake), SLC51A (bile-acid transport), HMGCS2 (ketogenesis), and ABCG2 (xenobiotic efflux).
- **Gene-gene relationship:** These genes are co-expressed in differentiated colonic epithelium and share pathways, but no direct physical interaction is implied.

### 7. DEFB1 / B4GALNT2 / GCNT2 / MEP1B
- **Direction:** Downregulated in UC
- **Role:** Epithelial antimicrobial barrier and glycosylation.
- **Gene-gene relationship:** Likely co-expressed in mature epithelial cells and functionally related to mucosal barrier formation, but direct physical interactions are not established by this dataset.

### 8. CTLA4 / DAPP1 / immunoglobulin heavy-chain locus
- **Direction:** Upregulated in UC
- **Role:** Adaptive immune activation: CTLA4 represents T-cell checkpoint/regulatory activity; DAPP1 and immunoglobulin reflect B-cell/plasma-cell activation.
- **Gene-gene relationship:** These represent different lymphocyte lineages; they are not directly interacting partners. Their co-upregulation suggests coordinated adaptive immune activation, not a direct physical module.

---

## 4. Validation priorities

### Priority 1: Cell-composition and epithelial/immune deconvolution
- **Classification:** Confounding or composition check  
- **Why:** Mucosal tissue is a mixture of epithelium, immune cells, stroma, and vasculature. Many top upregulated genes are neutrophil/alarmin genes, and many downregulated genes are epithelial transporters. This pattern could reflect altered cell proportions, not solely cell-intrinsic expression changes.  
- **Current dataset evidence:** S100A8, LCN2, CHI3L1, and CXCL1/2/3 are strongly upregulated; AQP8, SLC51A, and HMGCS2 are strongly downregulated.  
- **External evidence:** Histology and single-cell studies of UC show dense neutrophil infiltrates and epithelial damage/loss.  
- **Next step:** Single-cell RNA-seq or sorted epithelial/CD45+ populations; computational deconvolution; spatial transcriptomics or immunohistochemistry for key markers.  
- **Current status:** The presence of compositional shift in UC is established; the exact per-cell gene programs are **supported hypotheses**, not yet established from this bulk dataset.

### Priority 2: SLC6A14 and DUOX2/DUOXA2 functional epithelial axis
- **Classification:** Mechanistic hypothesis  
- **Why:** Both are strongly upregulated, epithelial-expressed, and biologically plausible drivers or responders in UC. SLC6A14 is targetable; DUOX2 biology has genetic links to IBD.  
- **Current dataset evidence:** Strong upregulation of SLC6A14, DUOX2, and DUOXA2.  
- **External evidence:** Literature implicates SLC6A14 in IBD and DUOX2 mutations in IBD-like disease; however, DUOX2 upregulation in active disease conflicts with the loss-of-function genetic association, so the direction of causality is uncertain.  
- **Next step:** Human colonic organoid studies with inflammatory cytokines; knockdown or pharmacological inhibition in colitis models; measurement of ROS, amino-acid uptake, and barrier function.  
- **Current status:** **Supported/exploratory hypothesis**, not established causal mechanism.

### Priority 3: Biomarker validation of S100A8, LCN2, and CHI3L1
- **Classification:** Biomarker  
- **Why:** S100A8 is part of fecal calprotectin, already a clinical UC biomarker. LCN2 and CHI3L1 are candidate complementary markers.  
- **Current dataset evidence:** Strong mRNA upregulation of S100A8, LCN2, and CHI3L1.  
- **External evidence:** Fecal calprotectin is established in IBD; fecal/serum NGAL and CHI3L1 have been associated with intestinal inflammation.  
- **Next step:** Paired fecal/serum/tissue protein measurements; correlation with endoscopic disease activity; prospective validation cohort.  
- **Current status:** S100A8/calprotectin is **established evidence**; LCN2 and CHI3L1 are **supported hypotheses**.

### Priority 4: ECM remodeling and fibrosis network
- **Classification:** Interaction / network hypothesis  
- **Why:** MMP3, TIMP1, TNC, PDPN, and PRRX1 are co-upregulated, suggesting a coordinated matrix-remodeling/mesenchymal response. This may affect mucosal healing, structuring, and fibrosis.  
- **Current dataset evidence:** Co-expression in bulk tissue only; no spatial or cellular localization.  
- **External evidence:** MMP3, TIMP1, and TNC are implicated in IBD tissue remodeling; PRRX1 is linked to EMT/mesenchymal differentiation in other systems.  
- **Next step:** Multiplex imaging/RNAscope to localize MMP3, TIMP1, TNC, and PDPN; protease activity assays; organoid–fibroblast co-cultures.  
- **Current status:** **Supported hypothesis**, not established.

### Priority 5: Epithelial metabolic/barrier suppression as cause versus consequence
- **Classification:** Mechanistic hypothesis  
- **Why:** Downregulation of SLC16A1/MCT1, HMGCS2, AQP8, and DEFB1 may represent either a consequence of inflammation or a primary epithelial vulnerability. This distinction matters for therapy.  
- **Current dataset evidence:** Broad coordinated downregulation of mature colonocyte metabolic and barrier genes.  
- **External evidence:** Butyrate/MCT1 and ketogenesis are important for colonocyte energy metabolism; reduced AQP8 and HMGCS2 have been reported in inflamed/dysplastic intestinal tissue.  
- **Next step:** Treat human colonic organoids with UC-relevant cytokines; measure butyrate uptake, metabolic function, and differentiation markers; compare sorted epithelial transcriptomes.  
- **Current status:** **Supported hypothesis**; causality is unresolved.

---

## 5. Evidence grounding

- **Direct evidence from input dataset:** Differential expression only. The dataset establishes statistically strong associations, but not protein levels, cell localization, causality, or clinical outcome.
- **Pathway/ontology evidence:** GO/KEGG/Reactome/Hallmark annotations support grouping the genes into the programs above, but these are annotations, not independent biological validations.
- **Protein interaction or regulatory evidence:** Literature supports direct or regulatory interactions for MMP3–TIMP1, CXCL1/2/3–CXCR2, IL1RN–IL1R, S100A8–S100A9, and DUOX2–DUOXA2. These are external to the current dataset and should not be treated as if they were demonstrated by the expression table.
- **Disease-association evidence:** Several genes (SLC6A14, DUOX2, S100A8, LCN2, CHI3L1, MMP3, AQP8, HMGCS2) have prior IBD associations in the published literature. This is convergent, but not fully independent: some prior expression datasets may have similar bulk-tissue composition limitations.
- **Genetic evidence:** There is genetic evidence for DUOX2/DUOXA2 in IBD-like disease, and possibly for SLC6A14 in IBD. However, genetic association does not determine whether upregulation in active UC is protective or pathogenic.
- **Drug/therapeutic evidence:** Drug-target relationships exist for IL1RN, CTLA4, DUOX2, SLC6A14, and others, but drug availability or prior use in other diseases is not evidence of efficacy in UC.
- **Conflicting evidence:** The main conflict is DUOX2: genetic loss-of-function is associated with IBD, yet DUOX2 mRNA is increased in active UC. Another conflict is antimicrobial programming: inducible alarmins/ROS are up, while constitutive DEFB1 is down. These are not contradictory at the pathway level but make simplified interpretations unsafe.

---

## 6. Limitations and alternative explanations

1. **Tissue and cell-composition differences.**  
   The bulk colonic mucosal sample mixes epithelial, immune, stromal, and microbial-associated cells. The upregulation of neutrophil/alarmin genes and downregulation of epithelial transporters strongly suggests a compositional shift. This can be tested by single-cell/sorted-population RNA-seq, deconvolution, and spatial methods.

2. **Disease severity, treatment exposure, and clinical heterogeneity.**  
   No clinical metadata are provided. UC severity, extent of inflammation, prior corticosteroids, 5-aminosalicylates, immunomodulators, or biologics can alter immune and metabolic gene expression. Results should be replicated in a clinically annotated cohort.

3. **Probe/platform ambiguity and tissue-irrelevant genes.**  
   Several entries map to multiple genes or uncharacterized probes:  
   - LOC100290146|IGHV4-31|IGHM|IGHG1|IGH  
   - CYP2B7P|CYP2B6  
   - NAT8B|NAT8  
   - UBD|GABBR1  
   - C1QTNF3|AMACR  
   - PROBE_241592_PM_at and PROBE_227140_PM_at  
   Some genes, such as PDE6A, TEX11, or ABCB11, are not obviously expected in colonic mucosa and may reflect cross-hybridization, rare cell types, or technical artifacts. qPCR/RNA-seq validation is needed.

4. **Broad or nonspecific pathway enrichment.**  
   Programs such as “inflammatory response” and “metabolic pathways” are broad. Their apparent enrichment may partly reflect overlapping annotations rather than a single unifying biology. More focused gene-set analyses and independent replication are needed.

5. **Association-versus-causation ambiguity.**  
   Differential expression does not establish whether a gene drives UC, is a response to inflammation, or is a compensatory protective mechanism. This is particularly relevant for DUOX2, CTLA4, IL1RN, TIMP1, and the downregulated metabolic program. Perturbation experiments are required before causal claims are made.

---

## Summary of confidence

The strongest conclusions are that active UC mucosa shows:

- A coordinated innate inflammatory/neutrophil/alarmin response.
- A tissue-remodeling/EMT-like program.
- Loss of mature colonocyte metabolic, transport, detoxification, and barrier gene expression.
- Adaptive immune activation with B-cell/plasma-cell and T-cell checkpoint signals.

These are statistically well supported as expression programs. However, the causal roles of individual genes, the cell types responsible, and whether these changes are primary drivers or secondary consequences of inflammation remain **supported hypotheses** rather than established mechanisms.
